Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Seattle, Washington 98195


RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.

Study summary:

OBJECTIVES: - Determine the maximum tolerated dose and toxicity of interleukin-2 in patients with stage IIB-IV mycosis fungoides. - Determine the response rate of patients treated with this regimen. - Determine the immunologic response to this regimen in peripheral blood leukocytes and serum of these patients. OUTLINE: This is a dose escalation study. Patients receive interleukin-2 (IL-2) subcutaneously on days 1-5 during weeks 1-3 and on days 1-3 and 5 during week 4. Treatment repeats every 4 weeks for 4 courses. Cohorts of 3-6 patients receive escalating doses of IL-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience dose-limiting toxicity. Six additional patients receive IL-2 at 1 dose level preceding the MTD. Patients are followed at least 3 times during year 1 and then annually thereafter. PROJECTED ACCRUAL: A total of 16-30 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Clinically and histologically proven diagnosis of 1 of the following: - Mycosis fungoides (MF) meeting 1 of the following conditions: - Stage IIB disease that has failed psoralen ultraviolet A (PUVA) light therapy and topical chemotherapy (mechlorethamine and/or carmustine) - Stage III disease with generalized erythroderma - Stage IV disease with biopsy proven nodal or visceral involvement - Sezary syndrome - Stage III MF with a minimum of 20% Sezary cells (based on total WBC) - No clinically significant ascites or pleural effusion - Clinically significant pleural effusion defined as shortness of breath with oxygen saturation less than 90% PATIENT CHARACTERISTICS: Age: - 18 to 80 Performance status: - Karnofsky 70-100% Life expectancy: - At least 16 weeks Hematopoietic: - See Disease Characteristics - WBC at least 3,500/mm^3 - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 11.5 g/dL Hepatic: - Bilirubin less than 2.5 times normal - SGOT less than 2.5 times normal Renal: - Creatinine no greater than 2.0 mg/dL - No nephrotic syndrome Cardiovascular: - No history of myocardial infarction or congestive heart failure - No symptomatic coronary artery disease - No clinically manifest hypotension - No severe hypertension - No arrhythmia on electrocardiogram - No edema - No contraindication to pressor agents Pulmonary: - See Disease Characteristics - No dyspnea at rest or severe exertional dyspnea Neurologic: - No significant CNS dysfunction, including any of the following: - Seizure disorder - Active cerebrovascular disease - Dementia or delirium Other: - No autoimmune disease, including psoriasis - No uncontrolled peptic ulcer disease - No uncontrolled infection - No history of adverse reaction to interleukin-2 - HIV and HTLV-I negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior systemic or topical chemotherapy (6 weeks since prior mitomycin or nitrosoureas) Endocrine therapy: - At least 1 week since prior corticosteroids - No concurrent corticosteroids Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - No prior organ allograft - At least 3 weeks since other prior major surgery Other: - At least 4 weeks since prior immunosuppressive therapy - At least 2 weeks since prior phototherapy (ultraviolet B [UVB] or PUVA light therapy) - No concurrent phototherapy (UVB or PUVA light therapy)

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Interleukin-2 in Treating Patients With Mycosis Fungoides

Official Title:

Phase 1 Trial of Subcutaneous [SC]; Outpatient Interleukin-2 for Patients With Advanced Mycosis Fungoides [Stage IIb, III, IV]

Overall Status:


Study Phase:

Phase 1



Minimum Age:

18 Years

Maximum Age:

80 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

University of Washington

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:John A. Thompson, MD
Study Chair
Seattle Cancer Care Alliance

Study Dates

Start Date:February 1995
Completion Date:July 2003
Completion Type:Actual
Primary Completion Date:July 2003
Primary Completion Type:Actual
Verification Date:November 2012
Last Changed Date:November 30, 2012
First Received Date:November 1, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Biological

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of Washington

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.